Tech Company Financing Transactions
IgGenix Funding Round
IgGenix, operating out of San Francisco, secured $40.00 in investment from Alexandria Venture Investments, AllerFund and Eli Lilly and Company.
Transaction Overview
Company Name
Announced On
2/7/2023
Transaction Type
Venture Equity
Amount
$40
Round
Series B
Investors
Alexandria Venture Investments (Lead Investor) (Joel Marcus)
private investors (Sean Parker)
Proceeds Purpose
The company intends to use the funds to advance its lead program to Phase 1 human clinical trials and expand its discovery platform to encompass additional IgE-mediated disease beyond allergy.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
329 Oyster Point Blvd. 3rd Floor
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
IgGenix is a privately-held biotechnology company taking a revolutionary approach to directly address food and other severe allergies by re-engineering key antibodies involved in the allergic cascade. IgGenix isolates and transforms allergen-specific IgE antibodies into IgG antibodies that are designed to alleviate and possibly prevent the allergic cascade.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jessica Grossman
Chief Scientific Officer
Richard Boismenu
Chief Technical Officer
Derek Croote
Browse more venture capital transactions:
Prev: 2/7/2023: VFlowTech venture capital transaction
Next: 2/7/2023: Rembrand venture capital transaction
Share this article
Where The Data Comes From
We report on all VC transactions involving tech companies. VC investment data records reported here come from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs